Provided by Tiger Fintech (Singapore) Pte. Ltd.

Moleculin Biotech

0.6651
+0.03715.91%
Post-market: 0.6560-0.0091-1.37%19:49 EDT
Volume:2.15M
Turnover:1.39M
Market Cap:20.09M
PE:-0.15
High:0.6899
Open:0.6000
Low:0.5920
Close:0.6280
Loading ...

Moleculin Biotech Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
01 Aug

Moleculin Biotech Inc. Announces Notice of Intent to Grant European Patent for Innovative Annamycin Formulation

Reuters
·
30 Jul

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

THOMSON REUTERS
·
30 Jul

Moleculin Biotech Inc. Appoints Industry Veteran Adriano Treve as Strategic Advisor to Boost Global Partnerships

Reuters
·
17 Jul

Moleculin Biotech Enters New Stock Offering Agreement

TIPRANKS
·
12 Jul

Moleculin Biotech Enters $6.5 Million At-The-Market Offering Agreement with Roth Capital

Reuters
·
12 Jul

Moleculin Biotech’s Clinical and Regulatory Advances Drive Buy Rating Amid Promising Phase 3 MIRACLE Study and FDA Feedback

TIPRANKS
·
10 Jul

Moleculin Biotech Gains Approval for Phase 2B/3 AML Study

TIPRANKS
·
09 Jul

Moleculin Biotech receives approval for pivotal Phase 2B/3 study of Annamycin

TIPRANKS
·
09 Jul

Moleculin Biotech Secures RAMPA Approval to Expand Phase 3 MIRACLE Clinical Trial into Georgia, Boosting Global Enrollment Efforts

Reuters
·
09 Jul

Favourable Signals For Moleculin Biotech: Numerous Insiders Acquired Stock

Simply Wall St.
·
03 Jul

Moleculin Biotech Faces Nasdaq Delisting Warning

TIPRANKS
·
28 Jun

Moleculin Biotech Inc. Receives Nasdaq Deficiency Notice for Falling Below Minimum Bid Price Requirement

Reuters
·
28 Jun

Roth MKM Remains a Buy on Moleculin Biotech (MBRX)

TIPRANKS
·
27 Jun

Moleculin Biotech Raises $5.9M in Public Offering

TIPRANKS
·
24 Jun

Walter V. Klemp, CEO and President, Reports Acquisition of Common Shares of Moleculin Biotech Inc

Reuters
·
24 Jun

Moleculin Biotech prices 16.08M shares at 37c in public offering

TIPRANKS
·
20 Jun

Moleculin Biotech Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Jun

Promising Developments and Regulatory Progress Drive Buy Rating for Moleculin Biotech’s Annamycin

TIPRANKS
·
18 Jun

Moleculin Participates in Virtual Investor “What This Means” Segment

GlobeNewswire
·
18 Jun